Insider Selling: Amicus Therapeutics (NASDAQ:FOLD) CEO Sells 77,926 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 77,926 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the completion of the transaction, the chief executive officer owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. This represents a 6.45% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Amicus Therapeutics Stock Up 1.0%

Shares of NASDAQ FOLD traded up $0.11 during mid-day trading on Wednesday, reaching $11.00. 6,284,691 shares of the company’s stock traded hands, compared to its average volume of 4,313,128. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The business has a 50-day simple moving average of $9.25 and a 200 day simple moving average of $7.72. The stock has a market cap of $3.39 billion, a P/E ratio of -274.93 and a beta of 0.46. Amicus Therapeutics, Inc. has a 1-year low of $5.51 and a 1-year high of $11.14.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.12 by $0.05. The business had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The firm’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.10 EPS. On average, analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Institutional Investors Weigh In On Amicus Therapeutics

Institutional investors have recently made changes to their positions in the stock. Strs Ohio bought a new stake in shares of Amicus Therapeutics during the 1st quarter valued at $30,000. ANTIPODES PARTNERS Ltd bought a new position in Amicus Therapeutics in the 3rd quarter worth about $31,000. Osaic Holdings Inc. grew its holdings in Amicus Therapeutics by 450.1% during the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Amicus Therapeutics by 472.6% during the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 3,677 shares during the period. Finally, Allworth Financial LP lifted its stake in Amicus Therapeutics by 36.3% in the 3rd quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 1,246 shares in the last quarter.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on FOLD shares. JPMorgan Chase & Co. upped their price target on Amicus Therapeutics from $18.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, November 6th. The Goldman Sachs Group upped their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 5th. Citigroup initiated coverage on shares of Amicus Therapeutics in a report on Wednesday. They set a “buy” rating and a $17.00 price target on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday. Finally, Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Amicus Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $17.29.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.